BingX Introduces Copy Trading 2.0: Greater Control, Transparency, and Flexibility
PANAMA CITY, June 12, 2025 /CNW/ -- BingX, a global leading cryptocurrency exchange and Web3 AI company, has launched its perpetual futures Copy Trading 2.0, a major upgrade to its popular social trading system. This enhanced version is designed to empower users with greater control, transparency, and data-driven decision-making. With Copy Trading 2.0, BingX introduces a suite of powerful new features that simplify the trading experience, offering users more intuitive access to trading data, improved risk management tools, and enhanced flexibility when copying top traders.
Dedicated Sub-Accounts for Simplified Trading
BingX has introduced dedicated sub-accounts for each follower, streamlining trade and fund management. These individual sub-accounts help users keep their trades organized. In addition, the system now automatically mirrors the trader's leverage and margin mode, enabling followers to replicate trades with the exact same settings for a more accurate and consistent copy trading experience.
Optimized Logic with Clear Calculations
The new system also allows multiple open orders to automatically merge into one. This makes it easier to calculate profits and losses accurately, with clear one-to-one matching between opening and closing positions. The result is a more flexible, straightforward process that reduces errors and simplifies trade management.
Unified Data for Greater Transparency
All copy trading data now comes directly from perpetual futures accounts, ensuring consistency and accuracy across the board. Both traders and followers' account assets, positions, balance records, and trading histories are aligned with real-time futures data. This unified data system allows users to track performance more effectively, providing transparency and boosting confidence in their risk management and profitability analysis.
"A cleaner interface with improved data tracking and a fairer system benefits both traders and their followers," Vivien Lin, Chief Product Officer of BingX, added: "Copy Trading 2.0 is a direct response to user feedback. We've always believed in our user-first vision and listening to our community. There are plenty of additional upgrades like more flexible trial funds for users to explore as they engage with the platform. Our goal is to continuously evolve and provide the best tools to support our users' crypto trading journey."
About BingX
Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /CNW/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES) Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm) Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design Follow-Up: Patients will be monitored for up to 60 months (5 years) Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Cision Canada
2 hours ago
- Cision Canada
Concordia Shanghai Breaks Ground on Visionary New Rittmann Center
State-of-the-art facility will transform student life through the arts, athletics, and wellness. SHANGHAI, June 13, 2025 /CNW/ -- Concordia International School Shanghai is set to break ground on a major redevelopment of the Rittmann Center, expanding the iconic facility into a modern, 13,710-square-meter multi-purpose hub designed to support student excellence in academics, the arts, athletics, and wellness. Named after former Head of School Dr. David Rittmann, the Rittmann Center was first completed in December 2007, with a purpose to enhance the school's creative arts education. More than five times the size of the current building, the new Rittmann Center marks one of the largest facility investments in the school's history. Designed to serve students across all divisions, it embodies Concordia's commitment to innovation, sustainability, and holistic education. The new center will house: An eight-lane, 25-meter competition pool with spectator seating for 240 A professional-grade theater with seating for over 500—a major upgrade from the current 330 Purpose-built music classrooms for band, choir, and strings Six dedicated practice rooms, three ensemble rooms, and a 170m² drama studio Four expansive art studios filled with natural light and designed for creative exploration Two underground floors and four above ground, maximizing space while maintaining a compact campus footprint A green roof and infrastructure built to meet LEED II certification standards, continuing the school's focus on sustainability Architects from Ennead have worked closely with the school to shape a building that's not only functional but inspiring, incorporating advanced acoustic treatments, energy-efficient HVAC systems, and student-centered design principles to support 21st-century learning and performance. "The Rittmann Center has long been a space where students shine," said Dr. Eric Semler, Head of School. "This new facility will take that to the next level—empowering students to explore their passions, build confidence, and thrive in a community that celebrates their talents." Construction will begin after the end of the 2024–25 school year and is expected to be completed by July 2027. To minimize disruption to learning, the school has implemented: Phased construction scheduling tied to school breaks Sound barriers, vibration dampeners, and dust suppression systems Dedicated traffic flow systems to avoid student movement areas "This is more than a building project - it's an investment in our students' future. It's about creating an environment where future generations can learn, perform, and grow," added Dr. Semler. About Concordia International School Shanghai Founded in 1998, Concordia International School Shanghai is a co-educational day school that offers a comprehensive American-style education to students from Preschool through High School. Located in Jinqiao, an international community in Shanghai's Pudong New Area, we are dedicated to cultivating the unique gifts of our students in any areas they are passionate about. Our approach focuses on nurturing every student through a journey of personal and academic growth, offering innovative academic programs, enriching extracurricular activities, and instilling strong character and values.
Cision Canada
3 hours ago
- Cision Canada
AtkinsRéalis announces partnership with BWT Alpine Formula One Team Français
MONTREAL, June 13, 2025 /CNW/ - BWT Alpine Formula One Team today announces a partnership with AtkinsRéalis Group Inc. (TSX: ATRL), a world-class engineering services and nuclear organization that prioritizes people, data and technology to transform the world's infrastructure and energy systems. Drawing on its extensive experience in key markets such as aerospace, defense, nuclear energy, and complex high-performance engineering and design, AtkinsRéalis will collaborate with BWT Alpine Formula One Team on joint initiatives. The collaboration will leverage shared resources such as technology, expertise, and facilities to achieve mutual objectives, including the development of an engineering academy to build capabilities across the partnership. This partnership aspires to foster technological innovation, uphold engineering excellence, and develop new ways of working within their respective fields. Ian L. Edwards, President and CEO, AtkinsRéalis: "We are proud to partner with BWT Alpine Formula One team, starting at this weekend's Canadian Grand Prix. By combining our global expertise with BWT Alpine Formula One Team's pioneering spirit, we're creating a relationship where seasoned engineers and rising talent can grow together, challenge conventions, and deliver real-world impact in performance, sustainability, and technological excellence. We look forward to working together to train and develop the engineers of the future." David Sanchez, Executive Technical Director, BWT Alpine Formula One Team: "We are excited to enter into this partnership with AtkinsRéalis; as competitors in Formula One, cutting-edge engineering is the most important part of the team's operations. The wide variety of groundbreaking technology mastered by AtkinsRéalis excellently combines with the fast-paced world of motorsport and we are excited to begin this new relationship this weekend in Montreal and beyond." About AtkinsRéalis Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-class engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world's infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services, Nuclear and Capital. News and information are available at or follow us on LinkedIn. About BWT Alpine Formula One Team BWT Alpine Formula One Team competes in the FIA Formula One World Championship with Grand Prix race winner Pierre Gasly and Franco Colapinto under the leadership of Executive Advisor, Flavio Briatore. The team, bought by the Benetton Family in 1986, was moved to Enstone, Oxfordshire, in 1992 where it is still based today. Renault bought the Italian-run team in 2000 and rebranded as Alpine F1. The team has a winning legacy, having won the Formula One World Championship seven times including the Drivers' World Championship [1994, 1995, 2005 and 2006] with Michael Schumacher and Fernando Alonso, and the Constructors' World Championship [1995, 2005 and 2006]. The team's most recent triumph came at the 2021 Hungarian Grand Prix, the 50th victory overall. The team finished the 2024 season strongly with two podium finishes and ended the year sixth place overall in the Constructors' Championship. For more information, please head to Forward-Looking Statements References in this press release to the "Company", "AtkinsRéalis", "we", us" and "our" mean, as the context may require, AtkinsRéalis Group Inc. or all or some of its subsidiaries or joint arrangements or associates. Statements made in this press release that describe the Company's expectations or strategies constitute "forward-looking statements", which can be identified by the use of the conditional or forward-looking terminology such as "estimates", "expects", "forecasts", "intends", "may", "objective", "plans", "projects", "should", "will", "likely", or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. The Company cautions that, by their nature, forward-looking statements involve risks and uncertainties, and that its actual actions or results could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Company's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Company's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements made in this press release are based on a number of assumptions believed by the Company to be reasonable as at the date hereof. The assumptions are set out throughout the Company's 2024 annual management disclosure & analysis ("2024 MD&A") (particularly in the sections entitled "Critical Accounting Judgments and Key Sources of Estimation Uncertainty" and "How We Analyze and Report our Results") filed with the securities regulatory authorities in Canada, available on SEDAR+ at and on the Company's website at under the "Investors" section. If these assumptions are inaccurate, the Company's actual results could differ materially from those expressed or implied in such forward-looking statements. In addition, important risk factors could cause the Company's assumptions and estimates to be inaccurate and actual results or events to differ materially from those expressed in or implied by these forward-looking statements. Those risks are identified in the 2024 MD&A (particularly in the section entitled "Risk and Uncertainties"), as may be updated from time to time in the Company's interim quarterly MD&A, are not exhaustive. The forward-looking statements herein reflect the Company's expectations as at the date of this press release and are subject to change after this date. The Company does not undertake to update publicly or to revise any such forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement.
